Background/Aims Liver congestion due to heart failure in patients with valvular heart disease (VHD) can result in an overestimate of the liver stiffness (LS) as assessed by transient elastography (TE). This prospective pilot study investigated the dynamics of LS during the perioperative valve operation period. Methods Thirty-two patients who underwent a valve operation (case) and 12 who underwent a varicose vein operation (control) were prospectively enrolled. LS and cardiologic parameters at three time points [baseline, post-operative day (POD)7, and POD90] were collected. Results LS at three time points were consistently higher in the case group than those in the control group, although all participants did not show evidence of underlying chronic liver disease (all P<0.05). In the case group, LS at POD7 increased slightly from the LS at baseline (median 7.9→8.4 kPa, P = 0.816), whereas LS at POD90 decreased significantly from the LS at POD7 (median 8.4→6.0 kPa; P = 0.026). LS was significantly correlated with N-terminal-pro brain natriuretic peptide (NT-proBNP) (ρ = 0.412), left ventricular ejection fraction (ρ = ？0.494), and central venous pressure during the operation (ρ = 0.555) at baseline (all P<0.05). LS was significantly correlated with NT-proBNP (ρ = 0.526) and right ventricular pressure (ρ = 0.572) at POD7, whereas LS was significantly correlated with NT-proBNP (ρ = 0.590) at POD90 (all P<0.05). Conclusions LS can be overestimated in patients with VHD due to hepatic congestion. However, LS can be dynamically reversed during the perioperative period reflecting the restoration of cardiac function after a successful operation.
References
[1]
Foucher J, Chanteloup E, Vergniol J, Castéra L, Le Bail B, et al. (2006) Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55: 403–408. doi: 10.1136/gut.2005.069153
[2]
Ganne Carrié N, Ziol M, de Ledinghen V, Douvin C, Marcellin P, et al. (2006) Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 44: 1511–1517. doi: 10.1002/hep.21420
[3]
Chon YE, Choi EH, Song KJ, Park JY, Kim DY, et al. (2012) Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS ONE 7: e44930–e44930. doi: 10.1371/journal.pone.0044930
[4]
Friedrich Rust M, Ong M, Martens S, Sarrazin C, Bojunga J, et al. (2008) Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 134: 960–974. doi: 10.1053/j.gastro.2008.01.034
[5]
Arena U, Vizzutti F, Corti G, Ambu S, Stasi C, et al. (2008) Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 47: 380–384. doi: 10.1002/hep.22007
[6]
Sagir A, Erhardt A, Schmitt M, H？ussinger D (2008) Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology 47: 592–595. doi: 10.1002/hep.22056
[7]
Coco B, Oliveri F, Maina AM, Ciccorossi P, Sacco R, et al. (2007) Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. Journal of Viral Hepatitis 14: 360–369. doi: 10.1111/j.1365-2893.2006.00811.x
[8]
Kim SU, Han K, Park JY, Ahn SH, Chung MJ, et al. (2009) Liver stiffness measurement using FibroScan is influenced by serum total bilirubin in acute hepatitis. Liver International 29: 810–815. doi: 10.1111/j.1478-3231.2008.01894.x
[9]
Millonig G, Reimann FM, Friedrich S, Fonouni H, Mehrabi A, et al. (2008) Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology 48: 1718–1723. doi: 10.1002/hep.22577
[10]
Sharma P, Mishra SR, Kumar M, Sharma BC, Sarin SK (2012) Liver and spleen stiffness in patients with extrahepatic portal vein obstruction. Radiology 263: 893–899. doi: 10.1148/radiol.12111046
[11]
Bioulac Sage P, Couffinhal T, Foucher J, Balabaud CP (2009) Interpreting liver stiffness in the cirrhotic range. Journal of Hepatology 50: 423–424. doi: 10.1016/j.jhep.2008.11.003
[12]
Lebray P, Varnous S, Charlotte F, Varaut A, Poynard T, et al. (2008) Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency. Hepatology 48: 2089–2089. doi: 10.1002/hep.22594
[13]
Hopper I, Kemp W, Porapakkham P, Sata Y, Condon E, et al. (2012) Impact of heart failure and changes to volume status on liver stiffness: non-invasive assessment using transient elastography. European Journal of Heart Failure 14: 621–627. doi: 10.1093/eurjhf/hfs044
[14]
Millonig G, Friedrich S, Adolf S, Fonouni H, Golriz M, et al. (2010) Liver stiffness is directly influenced by central venous pressure. Journal of Hepatology 52: 206–210. doi: 10.1016/j.jhep.2009.11.018
[15]
Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, et al. (2004) American Society of Echocardiography recommendations for use of echocardiography in clinical trials. Journal of the American Society of Echocardiography 17: 1086–1119. doi: 10.1016/j.echo.2004.07.013
[16]
Saverymuttu SH, Joseph AE, Maxwell JD (1986) Ultrasound scanning in the detection of hepatic fibrosis and steatosis . British Medical Journal (Clinical Research Ed.1981) 292: 13–15. doi: 10.1136/bmj.292.6512.13
[17]
Simonovsky V (1999) The diagnosis of cirrhosis by high resolution ultrasound of the liver surface. British Journal of Radiology 72: 29–34.
[18]
Sandrin L, Fourquet B, Hasquenoph J, Yon S, Fournier C, et al. (2003) Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound in Medicine & Biology 29: 1705–1713. doi: 10.1016/j.ultrasmedbio.2003.07.001
[19]
Kim SU, Kim JK, Park JY, Ahn SH, Lee JM, et al. (2009) Variability in liver stiffness values from different intercostal spaces. Liver International 29: 760–766. doi: 10.1111/j.1478-3231.2009.02035.x
[20]
Kim SU, Choi GH, Han WK, Kim BK, Park JY, et al. (2010) What are 'true normal' liver stiffness values using FibroScan?: a prospective study in healthy living liver and kidney donors in South Korea. Liver International 30: 268–274. doi: 10.1111/j.1478-3231.2009.02172.x
[21]
Roulot D, Czernichow S, Le-Cl？siau H, Costes J, Vergnaud A, et al. (2008) Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. Journal of Hepatology 48: 606–613. doi: 10.1016/j.jhep.2007.11.020
[22]
Januzzi JL, van Kimmenade R, Lainchbury J, Bayes Genis A, Ordonez Llanos J, et al. (2006) NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. European Heart Journal 27: 330–337. doi: 10.1093/eurheartj/ehi631
[23]
Colli A, Pozzoni P, Berzuini A, Gerosa A, Canovi C, et al. (2010) Decompensated chronic heart failure: increased liver stiffness measured by means of transient elastography. Radiology 257: 872–878. doi: 10.1148/radiol.10100013
[24]
Kiesewetter CH, Sheron N, Vettukattill J, Hacking N, Stedman B, et al. (2007) Hepatic changes in the failing Fontan circulation. Heart 93: 579–584. doi: 10.1136/hrt.2006.094516
[25]
Hall C (2004) Essential biochemistry and physiology of (NT-pro)BNP. European Journal of Heart Failure 6: 257–260. doi: 10.1016/j.ejheart.2003.12.015
[26]
Levin ER, Gardner DG, Samson WK (1998) Natriuretic peptides. The New England Journal of Medicine 339: 321–328. doi: 10.1056/nejm199807303390507
[27]
Mair J, Hammerer Lercher A, Puschendorf B (2001) The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clinical Chemistry and Laboratory Medicine 39: 571–588. doi: 10.1515/cclm.2001.093
[28]
Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA (2003) N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. European Heart Journal 24: 1735–1743. doi: 10.1016/j.ehj.2003.07.005
[29]
Bettencourt P, Azevedo A, Pimenta J, Fri？es F, Ferreira S, et al. (2004) N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 110: 2168–2174. doi: 10.1161/01.cir.0000144310.04433.be
[30]
Woo JJ, Koh YY, Kim HJ, Chung JW, Chang KS, et al. (2008) N-terminal pro B-type natriuretic peptide and the evaluation of cardiac dysfunction and severity of disease in cirrhotic patients. Yonsei Medical Journal 49: 625–631. doi: 10.3349/ymj.2008.49.4.625
[31]
Brookes CI, Kemp MW, Hooper J, Oldershaw PJ, Moat NE (1997) Plasma brain natriuretic peptide concentrations in patients with chronic mitral regurgitation. The Journal of Heart Valve Disease 6: 608–612.
[32]
Mayer SA, De Lemos JA, Murphy SA, Brooks S, Roberts BJ, et al. (2004) Comparison of B-type natriuretic peptide levels in patients with heart failure with versus without mitral regurgitation. The American Journal of Cardiology 93: 1002–1006. doi: 10.1016/j.amjcard.2004.01.008
[33]
Sutton TM, Stewart RA, Gerber IL, West TM, Richards AM, et al. (2003) Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. Journal of the American College of Cardiology 41: 2280–2287. doi: 10.1016/s0735-1097(03)00486-8
[34]
Feringa HH, Poldermans D, Klein P, Braun J, Klautz RJ, et al. (2007) Plasma natriuretic peptide levels reflect changes in heart failure symptoms, left ventricular size and function after surgical mitral valve repair. The International Journal of Cardiovascular Imaging 23: 159–165. doi: 10.1007/s10554-006-9138-z
